JeffreyABarnesMD

Instructor, Medicine, Massachusetts General Hospital, Harvard Medical School

Dr. Barnes is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2007 - 2010
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2005 - 2007
University of Illinois College of MedicineClass of 2004

PubMed

Delays in diagnosis in cutaneous T-cell lymphoma: A retrospective study on clinical course and time to death.
Bethany Brumbaugh, Beatrix Thompson, Allison Holt, Joseph Ebriani, Katherine Perlman
Journal of the American Academy of Dermatology. 2024-11-01
1 citations
KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes.
Bimarzhan Assatova, Robert Willim, Christopher Trevisani, Garrett Haskett, Khyati Maulik Kariya
Clinical Cancer Research. 2024-06-03
Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP.
Ronald Nemec, Marielle Scherrer-Crosbie, Jeremy S Abramson, Robert Redd, Hannah K Gilman
Leukemia & Lymphoma. 2024-06-01

Abstracts/Posters

Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation
Jeffrey A. Barnes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
Jeffrey A. Barnes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti‑CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cel...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018